2025
Germline-encoded recognition of peanut underlies development of convergent antibodies in humans
Marini-Rapoport O, Andrieux L, Keswani T, Zong G, Duchen D, Yaari G, Min J, Lytle I, Rosenberg A, Fucile C, Kobie J, Piepenbrink M, Sun T, Martin V, Yuan Q, Shreffler W, Seppo A, Järvinen K, Loeffler J, Ward A, Kleinstein S, Pedersen L, Fernández-Quintero M, Mueller G, Patil S. Germline-encoded recognition of peanut underlies development of convergent antibodies in humans. Science Translational Medicine 2025, 17: eadw4148. PMID: 40498852, DOI: 10.1126/scitranslmed.adw4148.Peer-Reviewed Original ResearchConceptsGene rearrangementsAllergen-specific IgG antibodiesPeanut-allergic childrenContext of food allergyGermline antibody repertoireDietary antigensAntibody gene rearrangementsPublic epitopesFood allergySerum IgGIgG antibodiesAntibody specificityImmunoglobulin GDiverse cohortAntibodiesAntibody repertoireAra h 2IgG recognitionEpitope-paratope interactionH-2AntigenGermlineIgGPeanut allergen Ara h 2Antigenicity of food proteinsTick feeding or vaccination with tick antigens elicits immunity to the Ixodes scapularis exoproteome in guinea pigs and humans
Hart T, Cui Y, Telford S, Marín-López A, Calloway K, Dai Y, Matias J, DePonte K, Jaycox J, DeBlasio M, Hoornstra D, Belperron A, Cibichakravarthy B, Johnson E, Alameh M, Dwivedi G, Hovius J, Bockenstedt L, Weissman D, Ring A, Fikrig E. Tick feeding or vaccination with tick antigens elicits immunity to the Ixodes scapularis exoproteome in guinea pigs and humans. Science Translational Medicine 2025, 17: eads9207. PMID: 40138454, PMCID: PMC12067475, DOI: 10.1126/scitranslmed.ads9207.Peer-Reviewed Original ResearchConceptsTick antigensTick resistanceVector of tick-borne pathogensAcquired tick resistanceTick-borne pathogensIxodes scapularis</i>Tick feedingAntitick vaccinesDetectable antibody responseGuinea pigsTicksTick bitesAntigen cocktailPigsPrimary vectorFeedingAntibody responseHumoral responseImmunogen candidateAntigenLyme diseaseImmunoglobulin GRepeated exposureIxodesNorth AmericaEstimating the Serotype-Specific Association Between the Concentration of Vaccine-Induced Serum Antibodies and Protection Against Pneumococcal Colonization
Wong A, Warren J, Fitch L, Perniciaro S, Dagan R, Weinberger D. Estimating the Serotype-Specific Association Between the Concentration of Vaccine-Induced Serum Antibodies and Protection Against Pneumococcal Colonization. The Journal Of Infectious Diseases 2025, jiaf106. PMID: 40036886, DOI: 10.1093/infdis/jiaf106.Peer-Reviewed Original ResearchHigher-valent PCVsPneumococcal conjugate vaccinePneumococcal colonizationVaccine-induced serum antibodiesRisk of colonizationSerum immunoglobulin GRandomized Controlled TrialsConjugate vaccinePCV13Clinical trialsSerum IgGImmune responseVaccinated childrenSevere diseaseVaccine effectivenessSerum antibodiesPCV20Serotype-specificImmunoglobulin GSerotypesColonIndirect protectionIgGVaccineTrials
2024
B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity
Bennett J, Pittock S, Paul F, Kim H, Irani S, O'Connor K, Patterson K, Smith M, Gunsior M, Mittereder N, Rees W, Cimbora D, Cree B. B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity. Annals Of Clinical And Translational Neurology 2024, 11: 2792-2798. PMID: 39222408, PMCID: PMC11514900, DOI: 10.1002/acn3.52171.Peer-Reviewed Original ResearchNeuromyelitis optica spectrum disorderAquaporin-4B cellsAquaporin-4 immunoglobulin GCirculating B cell subsetsAQP4-IgG titerN-MOmentum studyB-cell countsB cell subsetsBaseline to timePost Hoc AnalysisInebilizumab treatmentAQP4-IgGCD20<sup>+</sup>Subset countsGene signatureHoc AnalysisInebilizumabNo differenceImmunoglobulin GNeuromyelitisBaselineDisordered activityTitersSpectrum disorder
2023
Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open‐label extension
Nowak R, Breiner A, Bril V, Allen J, Khan S, Levine T, Jacobs D, Sahagian G, Siddiqi Z, Xu J, Macias W, Benatar M, Adams L, Genge A, Habib A, Hinton J, Holmlund T, Jacobs D, Lange D, Nicolle M, Phan H, Silvestri N, Small G, Yegiaian S. Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open‐label extension. Annals Of Clinical And Translational Neurology 2023, 11: 194-206. PMID: 38062618, PMCID: PMC10791011, DOI: 10.1002/acn3.51946.Peer-Reviewed Original ResearchAnti-acetylcholine receptor antibodiesGeneralized myasthenia gravisTotal immunoglobulin GMyasthenia gravisImmunoglobulin G subclassesReceptor antibodiesOpen-label extension studyG subclassesImmunoglobulin GMyasthenia Gravis ActivitiesPatient-administered therapyPreliminary clinical benefitsQuantitative Myasthenia GravisOpen-label extensionPlacebo-controlled trialPhase 2a trialWeekly subcutaneous injectionsReceptor monoclonal antibodyMyasthenia Gravis QualityStudy support further investigationSupport further investigationMyasthenia Gravis CompositeEligible patientsPrimary endpointSecondary endpointsCharacterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies
Zendt M, Carrillo F, Kelly S, Saturday T, DeGrange M, Ginigeme A, Wu L, Callier V, Ortega-Villa A, Faust M, Chang-Rabley E, Bugal K, Kenney H, Khil P, Youn J, Osei G, Regmi P, Anderson V, Bosticardo M, Daub J, DiMaggio T, Kreuzburg S, Pala F, Pfister J, Treat J, Ulrick J, Karkanitsa M, Kalish H, Kuhns D, Priel D, Fink D, Tsang J, Sparks R, Uzel G, Waldman M, Zerbe C, Delmonte O, Bergerson J, Das S, Freeman A, Lionakis M, Sadtler K, van Doremalen N, Munster V, Notarangelo L, Holland S, Ricotta E. Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies. Science Advances 2023, 9: eadh3150. PMID: 37824621, PMCID: PMC10569702, DOI: 10.1126/sciadv.adh3150.Peer-Reviewed Original ResearchConceptsHealthy volunteersIgG levelsDose of coronavirus diseaseImmune response to COVID-19 vaccinationResponse to COVID-19 vaccinationAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 infectionMessenger RNA-based vaccinesMedian IgG levelsOrgan transplant populationCoronavirus 2 infectionRNA-based vaccinesImmunomodulating treatmentTransplant populationDose 2Dose 3Prospective cohortCoronavirus diseaseDoseCOVID-19 vaccineOmicron BABivalent vaccineImmunoglobulin GVaccineIgGTracking B cell responses to the SARS-CoV-2 mRNA-1273 vaccine
de Assis F, Hoehn K, Zhang X, Kardava L, Smith C, Merhebi O, Buckner C, Trihemasava K, Wang W, Seamon C, Chen V, Schaughency P, Cheung F, Martins A, Chiang C, Li Y, Tsang J, Chun T, Kleinstein S, Moir S. Tracking B cell responses to the SARS-CoV-2 mRNA-1273 vaccine. Cell Reports 2023, 42: 112780. PMID: 37440409, PMCID: PMC10529190, DOI: 10.1016/j.celrep.2023.112780.Peer-Reviewed Original ResearchConceptsMemory B cellsB cell receptorB cellsAtypical memory B cellsInfection-naïve individualsTwo-dose SARSSARS-CoV-2 mRNAB cell responsesAntibody-secreting cellsMonth 6Protective immunityCell responsesCell receptorClonal expansionImmunoglobulin GEarly timepointsLater timepointsPlasmablastsVaccinationCD71TimepointsSurface proteinsCellsMultimodal single-cell analysisMRNAOccupational Risk Factors for SARS-CoV-2 Seropositivity in Healthcare Workers
Fazen L, Abad Q, Smith R, Santiago R, Liu J, Wisnewski A, Redlich C. Occupational Risk Factors for SARS-CoV-2 Seropositivity in Healthcare Workers. Journal Of Occupational And Environmental Medicine 2023, 65: 521-528. PMID: 36893070, PMCID: PMC10227858, DOI: 10.1097/jom.0000000000002831.Peer-Reviewed Original ResearchConceptsHealthcare workersRisk factorsSARS-CoV-2 immunoglobulin GSARS-CoV-2 seropositivityMultivariable-adjusted logistic regressionCox proportional hazards modelVaccine-induced immunityCOVID-19 risk factorsOccupational risk factorsLongitudinal cohort studyProportional hazards modelOccupational health interventionsRole of physiciansCOVID-19 riskCohort studyHazards modelHealth interventionsInternal medicineLogistic regressionResident physiciansImmunoglobulin GPhysiciansCOVID-19 pandemicSeropositivityVaccination
2021
Treatment and prevention of viral hepatitis in pregnancy
Dionne-Odom J, Cozzi GD, Franco RA, Njei B, Tita ATN. Treatment and prevention of viral hepatitis in pregnancy. American Journal Of Obstetrics And Gynecology 2021, 226: 335-346. PMID: 34516961, PMCID: PMC8907340, DOI: 10.1016/j.ajog.2021.09.002.Peer-Reviewed Original ResearchConceptsHepatitis BViral hepatitisHepatitis AHepatitis CAntiviral therapyPregnant womenVertical transmissionImmunoglobulin GActive hepatitis BBirth dose vaccineChronic viral hepatitisHigh clinical suspicionBlood-borne transmissionElevated viral loadRisk of acquisitionVertical transmission riskMedical history reviewTenofovir disoproxil fumarateAcquisition of infectionFecal-oral transmissionRoutine prenatal screeningRoute of infectionHerpes simplex virusVaccine seriesCesarean delivery
2013
Punctate pemphigus: an underreported direct immunofluorescence pattern
Ko CJ, McNiff JM. Punctate pemphigus: an underreported direct immunofluorescence pattern. Journal Of Cutaneous Pathology 2013, 41: 293-296. PMID: 24372009, DOI: 10.1111/cup.12272.Peer-Reviewed Original ResearchConceptsIntercellular depositionIntercellular IgG depositionDirect immunofluorescence studiesCases of pemphigusDirect immunofluorescence patternsDot-like patternIgG depositionPemphigus vulgarisDiagnostic findingsPemphigus foliaceusPemphigusImmunofluorescence patternImmunoglobulin GImmunofluorescence studiesPotential mechanismsIgGDIF studiesProtein array–based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis
Querol L, Clark PL, Bailey MA, Cotsapas C, Cross AH, Hafler DA, Kleinstein SH, Lee JY, Yaari G, Willis SN, O'Connor KC. Protein array–based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis. Neurology 2013, 81: 956-963. PMID: 23921886, PMCID: PMC3888197, DOI: 10.1212/wnl.0b013e3182a43b48.Peer-Reviewed Original ResearchConceptsCSF of patientsMultiple sclerosisNeurologic diseaseEpstein-Barr virus infectionImmunoglobulin GElevated immunoglobulin GInflammatory neurologic diseasesSubset of patientsLarger validation cohortRecombination signal binding proteinImmunoglobulin kappa J regionCSF autoantibodiesValidation cohortControl subjectsSerum reactivityAutoantigen candidatesHigh prevalenceVirus infectionPatientsAutoantibodiesCSFSclerosisArray-based profilingDiseaseELISA
2004
Molecular Characterization of Ancylostoma ceylanicum Kunitz-Type Serine Protease Inhibitor: Evidence for a Role in Hookworm-Associated Growth Delay
Chu D, Bungiro RD, Ibanez M, Harrison LM, Campodonico E, Jones BF, Mieszczanek J, Kuzmic P, Cappello M. Molecular Characterization of Ancylostoma ceylanicum Kunitz-Type Serine Protease Inhibitor: Evidence for a Role in Hookworm-Associated Growth Delay. Infection And Immunity 2004, 72: 2214-2221. PMID: 15039345, PMCID: PMC375216, DOI: 10.1128/iai.72.4.2214-2221.2004.Peer-Reviewed Original ResearchConceptsGrowth delayAdult hookwormsIron deficiency anemiaPolyclonal immunoglobulin GDeficiency anemiaHookworm infectionReverse transcription-PCRKunitz-type serine protease inhibitorImmunohistochemistry studiesBroad-spectrum inhibitorPartial protectionMajor causeImmunoglobulin GSerine protease inhibitorIntestinal proteasesThird-stage larvaeTranscription-PCRProtease inhibitorsAnemiaHookwormVivo roleMalnutritionInhibitorsInfected hostPancreatic elastasePreferential Presence of Decorin-Binding Protein B (BBA25) and BBA50 Antibodies in Cerebrospinal Fluid of Patients with Neurologic Lyme Disease
Fikrig E, Coyle PK, Schutzer SE, Chen M, Deng Z, Flavell RA. Preferential Presence of Decorin-Binding Protein B (BBA25) and BBA50 Antibodies in Cerebrospinal Fluid of Patients with Neurologic Lyme Disease. Journal Of Clinical Microbiology 2004, 42: 1243-1246. PMID: 15004083, PMCID: PMC356844, DOI: 10.1128/jcm.42.3.1243-1246.2004.Peer-Reviewed Original Research
2001
Glycosylation and the Immune System
Rudd P, Elliott T, Cresswell P, Wilson I, Dwek R. Glycosylation and the Immune System. Science 2001, 291: 2370-2376. PMID: 11269318, DOI: 10.1126/science.291.5512.2370.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigen PresentationAntigen-Antibody ReactionsAntigen-Presenting CellsAntigens, CD1Carrier ProteinsCollectinsComplement System ProteinsEndoplasmic ReticulumEpitopesGlycoproteinsGlycosylationHistocompatibility AntigensHumansImmune SystemImmunoglobulinsPolysaccharidesProtein FoldingT-LymphocytesViral Envelope ProteinsConceptsImmune systemMajor histocompatibility complex antigensAntigen-presenting cellsAdaptive immune responsesCellular immune systemHistocompatibility complex antigensHumoral immune systemT cell receptor complexRheumatoid arthritisMannose-binding lectinAutoimmune diseasesCell receptor complexT cellsImmune responseComplex antigensPeptide antigensComplement componentsImmunoglobulin GAntigenKey moleculesReceptor complexSpecific glycoformsGlycoproteinGlycopeptide antigensArthritis
1999
The Immunoglobulin (IgG) Antibody Response to OspA and OspB Correlates with Severe and Prolonged Lyme Arthritis and the IgG Response to P35 Correlates with Mild and Brief Arthritis
Akin E, McHugh G, Flavell R, Fikrig E, Steere A. The Immunoglobulin (IgG) Antibody Response to OspA and OspB Correlates with Severe and Prolonged Lyme Arthritis and the IgG Response to P35 Correlates with Mild and Brief Arthritis. Infection And Immunity 1999, 67: 173-181. PMID: 9864212, PMCID: PMC96293, DOI: 10.1128/iai.67.1.173-181.1999.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntigens, BacterialAntigens, SurfaceArthritis, InfectiousBacterial Outer Membrane ProteinsBacterial ProteinsBacterial VaccinesBorrelia burgdorferi GroupChildChild, PreschoolFemaleHumansImmunoglobulin GLipoproteinsLongitudinal StudiesLyme DiseaseMaleMiddle AgedSeverity of Illness IndexConceptsAntibody responseIgG antibodiesEarly arthritisLyme arthritisIgG responsesEarly infectionDuration of arthritisChronic Lyme arthritisIgG antibody responseSerial serum samplesBorrelia burgdorferi proteinsSubsequent arthritisB. burgdorferi proteinsSurface protein CC-terminal epitopeImmune responseArthritisSubsequent severityNatural historyLyme diseasePatientsSerum samplesImmunoglobulin GProtein CInfection
1998
Heat shock protein 70 of the agent of human granulocytic ehrlichiosis binds to Borrelia burgdorferi antibodies.
Ijdo J, Zhang Y, Anderson M, Goldberg D, Fikrig E. Heat shock protein 70 of the agent of human granulocytic ehrlichiosis binds to Borrelia burgdorferi antibodies. MSphere 1998, 5: 118-20. PMID: 9455892, PMCID: PMC121403, DOI: 10.1128/cdli.5.1.118-120.1998.Peer-Reviewed Original ResearchConceptsHuman granulocytic ehrlichiosisEhrlichial antigenHSP-70Borrelia burgdorferi antibodiesSerologic test resultsHeat shock protein 70Shock protein 70Burgdorferi antibodiesPatient seraGranulocytic ehrlichiosisLyme diseaseFirst weekHeat shock proteinsLyme disease spirochetePrior exposureImmunoglobulin GProtein 70Immunoblot analysisAntigenShock proteinsSerumAntibodiesPatientsIllnessIgG
1992
Anti-Ro autoantibody with cross-reactive binding to the heavy chain of immunoglobulin G.
Mamula M, Harley J. Anti-Ro autoantibody with cross-reactive binding to the heavy chain of immunoglobulin G. The Yale Journal Of Biology And Medicine 1992, 65: 277-87. PMID: 1290272, PMCID: PMC2589586.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, AntinuclearAutoantigensBinding, CompetitiveCattleCross ReactionsCyanogen BromideEnzyme-Linked Immunosorbent AssayHumansImmunoglobulin Fab FragmentsImmunoglobulin Fc FragmentsImmunoglobulin GImmunoglobulin Heavy ChainsLupus Erythematosus, SystemicPeptide FragmentsPrecipitin TestsRabbitsRibonucleoproteinsRNA, Small CytoplasmicConceptsSystemic lupus erythematosusRo antibodiesAutoimmune diseasesCross-reactive bindingSera of patientsAnti-Ro autoantibodiesHeavy chainAnti-Ro seraFragments of IgGRo proteinLupus erythematosusCyanogen bromide digestion fragmentsAntigenic stimulusRo seraPatient seraAutoantibodiesIgGFine specificityImmunologic determinantsRo responseImmunoglobulin GSerumAntibodiesRo particleRabbit serum
1982
Antibodies from patients with connective tissue diseases bind specific subsets of cellular RNA-protein particles.
Hardin JA, Rahn DR, Shen C, Lerner MR, Wolin SL, Rosa MD, Steitz JA. Antibodies from patients with connective tissue diseases bind specific subsets of cellular RNA-protein particles. Journal Of Clinical Investigation 1982, 70: 141-147. PMID: 6806318, PMCID: PMC370236, DOI: 10.1172/jci110587.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusLupus erythematosusRheumatoid arthritisPatient seraHepatitis B virus infectionB virus infectionPositive antinuclear antibodyRheumatic disease patientsJuvenile rheumatoid arthritisConnective tissue diseaseAntinuclear antibodiesSjögren's syndromeTissue diseaseDisease patientsAntigenic interrelationshipsSpecific subsetVirus infectionPatientsSuch seraMonoclonal immunoglobulin GImmunoglobulin GSerumAntibodiesAntigenic determinantsErythematosus
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply